PubAg

Main content area

Protective efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the European Avian-like H1N1 swine influenza virus in mice and pigs

Author:
Ruan, Bao-Yang, Wen, Feng, Gong, Xiao-Qian, Liu, Xiao-Min, Wang, Qi, Yu, Ling-Xue, Wang, Shuai-Yong, Zhang, Peng, Yang, Hai-Ming, Shan, Tong-Ling, Zheng, Hao, Zhou, Yan-Jun, Tong, Wu, Gao, Fei, Tong, Guang-Zhi, Yu, Hai
Source:
Veterinary microbiology 2018 v.222 pp. 75-84
ISSN:
0378-1135
Subject:
Influenza A virus, antibodies, genes, genetics, hemagglutination, human diseases, immunoglobulin G, inactivated vaccines, influenza vaccines, mice, neutralization, public health, secondary immunization, swine, swine influenza, viruses, China
Abstract:
Swine influenza A viruses (SIVs) causing outbreaks of acute, highly contagious respiratory disease in pigs also pose a potential threat to public health. European avian-like H1N1 (EA H1N1) SIVs are the predominant circulating viruses in pigs in China and also occasionally cause human infection. In this study, a high-growth reassortant virus (SH1/PR8), with HA and NA genes from a representative EA H1N1 isolate A/Swine/Shanghai/1/2014 (SH1) in China and six internal genes from the high-growth A/Puerto Rico/8/34 (PR8) virus, was generated by plasmid-based reverse genetics and tested as a candidate seed virus for the preparation of inactivated vaccine. The protective efficacy of inactivated SH1/PR8 was evaluated in mice and pigs challenged with wild-type SH1 virus. After primer and boost vaccination, the SH1/PR8 vaccine induced high-level hemagglutination inhibiting (HI) antibodies, IgG antibodies, and neutralization antibodies in mice and pigs. Mice and pigs in the vaccinated group showed less clinical phenomena and pathological changes than those in the unvaccinated group. In conclusion, the inactivated high-growth reassortant vaccine SH1/PR8 could induce high antibody levels and complete protection is expected against SH1 wild type SIV, and protection against heterologous EA H1N1 SIV needs further evaluation.
Agid:
6053870